<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="230">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382066</url>
  </required_header>
  <id_info>
    <org_study_id>APL-D-002-20</org_study_id>
    <secondary_id>2020-001993-31</secondary_id>
    <nct_id>NCT04382066</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19</brief_title>
  <acronym>APLICOV-PC</acronym>
  <official_title>Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PharmaMar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of
      pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome
      information of a novel coronavirus (SARS-CoV-2) from these pneumonia patients and developed a
      real-time reverse transcription PCR (real-time RT-PCR) diagnostic assay.

      Given no specific antiviral therapy for COVID-19 and the ready availability of plitidepsin as
      a potential antiviral agent, based on pre-clinical studies, this randomized, parallel and
      proof of concept trial will evaluate the safety of three doses of plitidepsin in patients
      hospitalized with COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Last December, a new infectious respiratory disease emerged in Wuhan, China. The agent that
      caused this pneumonia was identified as a new virus in the Coronaviridae family (SARS-CoV-2)
      and the clinical symptomatology associated with the virus has been named COVID-19. COVID-19
      is currently a public health emergency.

      Plitidepsin is an authorized drug in Australia for the treatment of multiple myeloma.
      Antiviral activity of plitidepsin has been analyzed in a human hepatoma cell line infected
      with the HCoV-229E-GFP virus, a virus similar to the SARS-CoV-2 virus.

      Taking into account that the available safety data from plitidepsin comes from patients with
      solid tumors that received treatment with a regimen of administration of plitidepsin for 5
      consecutive days, we propose a multicenter, randomized, proof-of-concept clinical trial to
      assess the safety profile of 3 different dose levels of plitidepsin administered three
      consecutive days, in adult patients with confirmed diagnosis of COVID-19 who require hospital
      admission.

      This study aims to assess safety and toxicity profile and also preliminary efficacy of
      plitidepsin at each dose level administered according to the proposed administration scheme
      in patients with COVID-19 who require hospital admission. Main objective is to select the
      recommended dose levels of plitidepsin for a future phase II / III efficacy study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of occurrence of Neutropenia ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Neutropenia ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Thrombocytopenia ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Thrombocytopenia ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Anemia ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Anemia ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Lymphopenia ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Lymphopenia ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of CPK increase ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with CPK increase ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Increase ALT and / or AST ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Increase ALT and / or AST ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Increase total bilirubin or direct bilirubin ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Increase total bilirubin or direct bilirubin ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Neurotoxicity ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Neurotoxicity ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of QT-QTc interval extension ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with QT-QTc interval extension ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of Other adverse events ≥ grade 3</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with Other adverse events ≥ grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients in whom treatment cannot be completed.</measure>
    <time_frame>At 3 days from the first dose of study treatment</time_frame>
    <description>Percentage of patients in whom treatment cannot be completed and the reasons.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with adverse events.</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with serious adverse events.</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with ECG abnormalities.</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients with ECG abnormalities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the viral load of SARS-CoV-2</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of change in the viral load of SARS-CoV-2 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative PCR test for COVID-19</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Time from inclusion/randomization to date of negative PCR test for COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients who die during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients requiring invasive mechanical ventilation and / or ICU admission</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients requiring invasive mechanical ventilation and / or ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients requiring non-invasive mechanical ventilation</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients requiring non-invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients requiring oxygen therapy</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Percentage of patients requiring oxygen therapy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plitidepsin 1.5 mg / day x 3 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plitidepsin 2.0 mg / day x 3 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plitidepsin 2.5 mg / day x 3 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plitidepsin 1.5 mg/day</intervention_name>
    <description>Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plitidepsin 2.0 mg/day</intervention_name>
    <description>Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.</description>
    <arm_group_label>Experimental 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plitidepsin 2.5 mg/day</intervention_name>
    <description>Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.</description>
    <arm_group_label>Experimental 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient who agrees to participate in the study by signing the informed consent.

          2. Men and women (non-pregnant) aged ≥18 years.

          3. COVID-19 infection confirmed by PCR obtained from nasopharyngeal exudate or sample
             from the lower respiratory tract.

          4. Patients who require hospitalization for COVID-19.

          5. Symptom onset at most within 10 days prior to study inclusion.

          6. Men and women with reproductive capacity should agree to use highly effective
             contraceptive methods during their participation in the study and in the 6 months
             following the last administration of plitidepsin.

          7. In addition, women participating in the study with reproductive ability must have a
             negative pregnancy test at enrollment.

        Exclusion Criteria:

          1. Patients participating in some other clinical trial for COVID-19 infection.

          2. Patients who are receiving treatment with antivirals, interleukin 6 receptor
             inhibitors or immunomodulatory drugs for COVID-19.

          3. Patients who are receiving treatment with chloroquine and derivatives.

          4. Evidence of multi-organ failure.

          5. Patients who require support with mechanical ventilation (invasive or non-invasive) at
             the time of inclusion.

          6. D-dimer&gt; 4 x UNL.

          7. Hb &lt;9 g / dL.

          8. Neutrophils &lt;1000 / mm3.

          9. Platelets &lt;100,000 / mm3.

         10. Lymphopenia &lt;800 / μL.

         11. GOT / GPT&gt; 3 X UNL.

         12. Bilirubin&gt; 1 X UNL.

         13. CPK&gt; 2.5 X UNL.

         14. Creatinine clearance &lt;30ml / min.

         15. Troponin elevation&gt; 1.5 x ULN.

         16. Clinically relevant heart disease (NYHA&gt; 2).

         17. Clinically relevant arrhythmia or previous history / presence of prolonged QT-QTc ≥
             450 ms.

         18. Pre-existing neuropathies of any type ≥ grade 2.

         19. Hypersensitivity to the active substance or to any of its excipients (macrogol
             glycerol ricinoleate and ethanol).

         20. Patients who require or are being treated with potent CYP3A4 inhibitors and inducers.

         21. Patients who for any reason should not be included in the study according to the
             evaluation of the research team.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Estrada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesús Fortún, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Barberán, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO HM MONTEPRÍNCIPE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria J Pontes</last_name>
    <phone>+ 34 91 8234631</phone>
    <email>mjpontes@pharmamar.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Belen Sopesen Veramendi</last_name>
    <phone>+ 34 91 44 44 500</phone>
    <email>bsopesen@pharmamar.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Hm Montepríncipe</name>
      <address>
        <city>Boadilla Del Monte</city>
        <state>Madrid</state>
        <zip>28660</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Barberán, Md</last_name>
      <email>barberan60@gmail.com</email>
    </contact>
    <investigator>
      <last_name>José Barberán, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Paredes, MD</last_name>
      <email>rparedes@irsicaixa.es</email>
    </contact>
    <investigator>
      <last_name>Roger Paredes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Soriano, MD</last_name>
      <email>asoriano@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Alex Soriano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Domingo, MD</last_name>
      <email>pdomingo@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Pere Domingo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María L Porras, MD</last_name>
      <email>mlporrasl@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>María L Porras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Vates, MD</last_name>
      <email>roberto.vates@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Roberto Vates, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Torralba, MD</last_name>
      <email>mtorralbag@gmail.com</email>
    </contact>
    <investigator>
      <last_name>mtorralbag@gmail.com Torralba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfredo Jover Sáenz, MD</last_name>
      <email>ajover.lleida.ics@gencat.cat</email>
    </contact>
    <investigator>
      <last_name>Alfredo Jover Sáenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Ancochea, MD</last_name>
      <email>juli119@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Julio Ancochea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paloma Gijón, MD</last_name>
      <email>palomigi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paloma Gijón, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Fortún, MD</last_name>
      <email>fortunabete@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jesús Fortún, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Estrada, MD</last_name>
      <email>vicente.estrada@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Vicente Estrada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosptial Quironsalud Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Guisado, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pablo Guisado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plitidepsin</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>Coronavirus</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data of the final publication of the study will be shared upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

